Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
Author:
Publisher
Proceedings of the National Academy of Sciences
Subject
Multidisciplinary
Reference37 articles.
1. Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
2. Does broad-spectrum -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?
3. Updated Functional Classification of β-Lactamases
4. Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria
5. Current Challenges in Antimicrobial Chemotherapy
Cited by 415 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Experimental and Theoretical Studies on the Reactions of Aliphatic Imines with Isocyanates;Chemistry – A European Journal;2024-01-30
2. Ceftazidime-avibactam induced renal disorders: past and present;Frontiers in Pharmacology;2024-01-22
3. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185;mBio;2024-01-05
4. Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops;Journal of Biological Chemistry;2024-01
5. The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam;Antibiotics;2023-12-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3